Browsing Tag
Ivonescimab
6 posts
Akeso secures fifth NMPA breakthrough therapy designation for ivonescimab, sharpening its first-line oncology ambitions in China
Akeso Inc. secures a fifth breakthrough therapy designation for ivonescimab. Find out why this matters for oncology strategy and investors.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
Summit Therapeutics launches global Phase III HARMONi-GI3 trial as ivonescimab enters colorectal cancer race
Find out how Summit Therapeutics and Akeso are betting on ivonescimab’s expansion into colorectal cancer and why investors see it as a defining moment for the biotech’s future.
Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step…
Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment…
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the…